Royal Bank of Canada Reaffirms “Outperform” Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They currently have a $943.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price indicates a potential upside of 59.33% from the […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They currently have a $943.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price indicates a potential upside of 59.33% from the […]
